Abbott Laboratories– tag –
-
FDA Approves World’s First Dual Glucose-Ketone Continuous Monitoring Wearable for Diabetes Patients: Early DKA Risk Detection Enabled
GIGAZINE Japan Overview GIGAZINE reports that the U.S. FDA has approved the world's first wearable device for continuous dual glucose and ketone monitoring in diabetes patients. This is Abbott's Libre Duo 10 Day, providing real-time data... -
FDA Clears First Continuous Glucose-Ketone Monitor: Abbott’s Libre Duo 10 Day Transforms Diabetes Care
Pharmacy Times USA Overview The FDA has authorized Abbott's Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for individuals aged 2 and older with diabetes. This marks the first continuous ketone monitoring wearable in t... -
HME News Reports: Abbott Gains FDA Clearance for Dual Sensing Technology, Marking New Step in DKA Prevention
HME News USA Overview HME News reports Abbott has received FDA authorization for its Libre Duo 10 Day system, which continuously monitors both glucose and ketones. This biowearable is designed to alert patients to rising ketone levels, c... -
Abbott’s Libre Duo 10 Day System Authorized by FDA: First US Continuous Dual Glucose-Ketone Wearable Provides Early DKA Warning for Diabetes Patients Ages 2+
Abbott & U.S. Food and Drug Administration (FDA) USA Overview Abbott's "Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System" has received FDA authorization, making it the first device in the US to continuously track ketone ... -
CNET Reviews 2026’s Latest Continuous Glucose Monitors (CGM), Highlighting FDA-Approved Dexcom Stelo’s Integration with Oura Ring
CNET USA Overview CNET's 2026 review of Continuous Glucose Monitors (CGM) features Abbott Freestyle Libre 2 and 3 Plus, Dexcom G7, and the notable Stelo by Dexcom, the first FDA-approved over-the-counter CGM in the US (2024). Stelo's sea... -
Abbott Submits Dual Glucose-Ketone Sensor ‘Libre Duo’ to US FDA for DKA Prevention After European CE Mark
MedTech Dive USA Overview Abbott has filed an FDA application to launch its dual glucose-ketone sensor, Libre Duo, in the U.S. after receiving Europe's CE mark. Approval is expected by year-end, with the device aiming to prevent diabetic... -
Senseonics Eversense 365 Receives FDA Approval as World’s First Year-Long Wearable CGM, Expanded Medicare Coverage to Reshape Market
Constancy Researchers America Overview Senseonics' Eversense 365 has secured FDA approval, becoming the world's first commercially available year-long implantable continuous glucose monitor (CGM). This innovation fundamentally improves p... -
Abbott Secures CE Mark for Libre Duo Glucose-Ketone Sensor, Accelerates European Rollout of Consumer Lingo Biosensor
FreeStyle Libre Summer 2026 update Europe Overview Abbott obtained the European CE Mark in May 2026 for Libre Duo and Libre Duo 10 Day, capable of measuring both glucose and ketones for 15 days, with European market launch planned within... -
Abbott and Google Health Announce Multi-Year Partnership to Revolutionize Personal Metabolic Health Management with AI-Powered Glucose Insights
PR Newswire USA Overview Abbott and Google Health have announced a multi-year partnership to integrate glucose insights from Abbott's Lingo biowearables with Google's AI and consumer technology, aiming to make personalized metabolic heal... -
Abbott and Medtronic Announce Global Partnership to Integrate FreeStyle Libre CGM Technology into Medtronic Insulin Delivery Systems
Abbott (via Facebook press release), Medtronic USA Overview Medtronic and Abbott have announced a global partnership to integrate Abbott's FreeStyle Libre sensing technology into Medtronic's insulin delivery systems. Under this agreement...
